JP Morgan Chase
ABEO icon

JP Morgan Chase’s Abeona Therapeutics ABEO Stock Holding History

JP Morgan Chase’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Buy
266,497
+245,150
+1,148% +$1.23M ﹤0.01% 4526
2025
Q4 		$112K Sell
21,347
-260,912
-92% -$1.31M ﹤0.01% 5823
2025
Q3 		$1.49M Sell
282,259
-548,873
-66% -$3.48M ﹤0.01% 4297
2025
Q2 		$4.72M Buy
831,132
+597,373
+256% +$3.4M ﹤0.01% 3232
2025
Q1 		$1.11M Buy
233,759
+233,745
+1,669,607% +$1.27M ﹤0.01% 4264
2024
Q4 		$78 Sell
14
-67,124
-100% -$413K ﹤0.01% 7049
2024
Q3 		$424K Buy
67,138
+28,606
+74% +$149K ﹤0.01% 5007
2024
Q2 		$163K Buy
38,532
+16,868
+78% +$86K ﹤0.01% 5261
2024
Q1 		$157K Buy
21,664
+21,650
+154,643% +$137K ﹤0.01% 5469
2023
Q4 		$70 Hold
14
– – ﹤0.01% 7161
2023
Q3 		$59 Hold
14
– – ﹤0.01% 6972
2023
Q2 		$56 Sell
14
-704
-98% -$2.46K ﹤0.01% 6736
2023
Q1 		$2K Buy
718
+704
+5,029% +$1.84K ﹤0.01% 6398
2022
Q4 		$0 Sell
14
-1
-7% -$4 ﹤0.01% 6493
2022
Q3 		$0 Hold
15
– – ﹤0.01% 6417
2022
Q2 		$0 Sell
15
-268
-95% -$1.36K ﹤0.01% 6423
2022
Q1 		$2K Sell
283
-49,572
-99% -$340K ﹤0.01% 6406
2021
Q4 		$420K Sell
49,855
-21,758
-30% -$400K ﹤0.01% 4943
2021
Q3 		$2M Sell
71,613
-9,267
-11% -$297K ﹤0.01% 3794
2021
Q2 		$3.15M Buy
80,880
+4,338
+6% +$177K ﹤0.01% 3436
2021
Q1 		$3.6M Buy
76,542
+50,428
+193% +$2.78M ﹤0.01% 3250
2020
Q4 		$1.02M Buy
26,114
+8,696
+50% +$296K ﹤0.01% 3944
2020
Q3 		$483K Buy
17,418
+3,537
+25% +$223K ﹤0.01% 4002
2020
Q2 		$1.01M Buy
13,881
+3,638
+36% +$251K ﹤0.01% 3506
2020
Q1 		$538K Buy
10,243
+9,821
+2,327% +$656K ﹤0.01% 3778
2019
Q4 		$35K Hold
422
– – ﹤0.01% 5222
2019
Q3 		$24K Buy
422
+68
+19% +$5.09K ﹤0.01% 5360
2019
Q2 		$42K Buy
354
+49
+16% +$8.21K ﹤0.01% 5238
2019
Q1 		$56K Sell
305
-3,754
-92% -$671K ﹤0.01% 5083
2018
Q4 		$725K Sell
4,059
-163
-4% -$35.5K ﹤0.01% 3934
2018
Q3 		$1.35M Sell
4,222
-2,898
-41% -$1.03M ﹤0.01% 3720
2018
Q2 		$2.85M Sell
7,120
-1,487
-17% -$650K ﹤0.01% 3132
2018
Q1 		$3.09M Sell
8,607
-784
-8% -$291K ﹤0.01% 2963
2017
Q4 		$3.72M Buy
+9,391
New +$3.88M ﹤0.01% 2914
2016
Q3 		– Sell
-19
Closed -$1K – 4506
2016
Q2 		$1K Buy
+19
New +$1.3K ﹤0.01% 4651

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase's ABEO Position: Q1 2026 in Review

JP Morgan Chase increased its Abeona Therapeutics (ABEO) stake by 1,148% in Q1 2026, buying an estimated $1.23M and bringing the position to 266,497 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #4526.

JP Morgan Chase first reported a position in ABEO in Q2 2016 and has held it in 35 quarters since. The position peaked at $4.72M in Q2 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • JP Morgan Chase held 266,497 shares of Abeona Therapeutics worth $1.13M as of Q1 2026.
  • JP Morgan Chase bought 245,150 Abeona Therapeutics shares in Q1 2026, an estimated $1.23M.
  • Abeona Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4526 holding.
  • JP Morgan Chase first reported a position in Abeona Therapeutics in Q2 2016 and has held it in 35 quarters since.
  • JP Morgan Chase's Abeona Therapeutics position peaked at $4.72M in Q2 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.